Financial advisers are realising they need to draw their attention to other investment options and not solely companies that are available via the ASX, according to Skaffold.
Skaffold general manager Chris Batchelor said assets in superannuation now “exceed the market capitalisation of the ASX” and advisers are now realising an “exclusive focus” of the ASX leads to too much concentration risk.
“We all know Australia is dominated by miners and the big 4 banks. Bringing global research into the mix expands the investment universe to include the world’s largest pharmaceutical, technology and luxury retail brands,” Mr Batchelor said.
These are highly profitable business, many of which have significant operations in Australia but are not accessible via the ASX,” he said.
Mr Batchelor also added that Skaffold’s technology is making it easier for advisers and investors to research an overseas company as it is an Australian company.
“Skaffold’s business has reached a critical point of scale, and we’re delighted to be able to pass on our success to our customers through a price reduction,” Mr Batchelor said.
“Skaffold offers a single research tool for multiple markets. Seeing the same patent pending visual interpretations of company data for Cochler, Pfizner, Bayer and Merck GKaA means investors can compare like-with-like regardless of where a stock is listed,” he said.
SUBSCRIBE TO THE IFA DAILY BULLETIN
11 Dec 2017Insurance engagement driven by advisersBy Jessica Yun
11 Dec 2017Kaplan pushes for new CPD regimeBy Staff Reporter
11 Dec 2017Senate approves AFCA billBy Annie Kane
11 Dec 2017Treasury reassess early super release rulesBy Miranda Brownlee
8 Dec 2017Dunsford embarks on acquisition huntBy Killian Plastow
8 Dec 2017ASIC reaffirms interest in reference check protocolsBy Killian Plastow
- view all